🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our SOS1::KRAS inhibitor BI-3406 manuscript got published Cancer Discovery:Combining SOS1::KRAS and MEK inhibition provides an attractive therapeutic concept for the majority of KRAS mutant cancers, including KRAS G12D, G12V, G12C and G13D Boehringer Ingelheim cancerdiscovery.aacrjournals.org/content/early/…

#PRESS: We’re teaming up with @MiratiTx to investigate the combination of our SOS1::pan-KRAS inhibitor with their #KRAS G12C selective inhibitor ➡ bit.ly/2FG54IF

Exciting news on Boehringer collaborating with Mirati on KRAS. Combining our SOS1 inhibitor with Mirati's KRAS-G12C in the clinic. boehringer-ingelheim.us/press-release/…

Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now published & formatted in the January 2021 issue of Cancer Discovery Cancer Discovery - cancerdiscovery.aacrjournals.org/content/candis… Marco Hofmann Norbert Kraut Tim Heffernan Boehringer Ingelheim

So exited to share our latest paper on SOS1 and the Discovery of BI-3406. Switching from a fluorine to a chlorine makes an inhibitor out of an activator. One Atom Makes All the Difference! Darryl B McConnell ACS Publications Bio & Med Chem Content pubs.acs.org/doi/10.1021/ac…

🚨⭐️MD Anderson & Boehringer Ingelheim have expanded their joint Virtual Research & Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer Tim Heffernan #AACR21 MD Anderson Cancer Center Boehringer Ingelheim app.bronto.com/public/?q=prev…

Great collaboration with Tim Heffernan and team at MD Anderson Cancer Center Check out our joint presentations #AACR21 #KRAS #first4patients Darryl B McConnell Marco Hofmann Daniel Gerlach Giulio Draetta Joe Marszalek

Excited to partner with Amgen, combining our clinical-stage SOS1::pan-KRAS inhibitor with sotorasib, the first US FDA approved KRAS-G12C inhibitor. #KRAS #first4patients

📢Expanding the reach of precision🎯oncology by drugging all #KRAS mutants - our new review is out in Cancer Discovery dx.doi.org/10.1158/2159-8…. Thanks to Marco Hofmann, Daniel Gerlach, Sandra Misale, Mark, and Norbert Kraut #First4Patients #TakingCancerOn

Just published: A Review on Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. bit.ly/33Nj7YI Norbert Kraut, Marco Hofmann, Daniel Gerlach, Sandra Misale, and Mark Petronczki

#RESEARCHERS: Our scientists foresee a concept of two potential future classes of #KRAS medicines - just published in Cancer Discovery! 👉 bit.ly/3nL3acD

🗓️Virtual conference upcoming "EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway" with a great line-up of speakers. Join on February 21-22, 2023 to get the latest updates in the field. Registration: eacr.org/conference/boe… EACR Boehringer Ingelheim

One of the best reviews this year on pharmacological targeting of KRAS - direct or indirect - is written by Norbert Kraut Sandra Misale Daniel Gerlach Marco Hofmann in Cancer Discovery - #OpenAccess & worth reading! aacrjournals.org/cancerdiscover…

Combined KRAS G12Ci + KRAS::SOS1i inhibition overcomes acquired resistance in Adagrasib-resistance CRC models - new pre-print from the Boehringer Ingelheim and MD Anderson Cancer Center partnership by venu☘️, Hengyu Lu and Marco Hofmann #KRAS #BI3406 #First4Patients doi.org/10.1101/2023.0…

Check out our work on KRAS G12Ci + KRAS::SOS1i as a viable combination therapy to address KRAS G12Ci resistance. This work is the result of Boehringer Ingelheim & MD Anderson Cancer Center partnership. #KRAS Daniel Gerlach Norbert Kraut Marco Hofmann KRASKickers biorxiv.org/content/10.110…

Looking forward to an exciting program of the EACR Boehringer Ingelheim virtual conference "Drugging and Regulating the MAP Kinase Pathway" co-organized with #ReneBernards Marisol Soengas Marco Hofmann Ralph Neumüller So many developments in this field and challenges we need to tackle!

The first session of #eacrMAPKpathway is underway with Marco Hofmann Boehringer Ingelheim introducing the interplay between inhibitors of SOS1 and KRAS Combination with SOS1i overcomes induced resistance to KRAS-G12Ci Does the upregulation of MRAS and RASGRP1 help explain resistance?

#AACR23: For more on Beating #KRAS, don't miss this Cancer Discovery review - Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants Marco Hofmann Daniel Gerlach Sandra Misale Norbert Kraut aacrjournals.org/cancerdiscover…

Thanks for including our paper published in Cancer Discovery describing BI-3406, a potent and selective SOS1-KRAS interaction inhibitor. aacrjournals.org/cancerdiscover… Marco Hofmann Darryl B McConnell Dirk Kessler Daniel Gerlach Tim Heffernan #KRAS #AACR23

Out now in Nature Cancer. Our brand-new paper shows co-targeting of KRASG12C plus SOS1 as strategy for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors. Thanks to MD Anderson Cancer Center, Tim Heffernan and team and congrats to the Boehringer Ingelheim #KRAS team nature.com/articles/s4301…